Answers are grounded in this paper and cite their sources.
A novel CT contrast agent denoted as BaYbF(5) @SiO(2) @PEG is presented. The as-prepared nanoparticles exhibit significantly enhanced contrast efficacy relative to clinical iodinated agents and maintain higher X-ray attenuation at different voltages, suitable for diagnostic imaging of various patients. Prolonged circulation time in vivo and low toxicity mean the nanoparticles perform excellently in in-vivo X-ray CT angiography.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: